The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Minireview: The Glucagon-Like Peptides
Abstract
The glucagon-like peptides GLP-1 and GLP-2 are produced in enteroendocrine L cells of the small and large intestine and secreted in a nutrient-dependent manner. GLP-1 regulates nutrient assimilation via inhibition of gastric emptying and food intake. GLP-1 controls blood glucose following nutrient absorption via stimulation of glucose-dependent insulin secretion, insulin biosynthesis, islet proliferation, and neogenesis and inhibition of glucagon secretion. Experiments using GLP-1 antagonists and GLP-1 receptor-/- mice indicate that the glucoregulatory actions of GLP-1 are essential for glucose homeostasis. In the central nervous system, GLP-1 regulates hypothalamic-pituitary function and GLP-1-activated circuits mediate the CNS response to aversive stimulation. GLP-2 maintains the integrity of the intestinal mucosal epithelium via effects on gastric motility and nutrient absorption, crypt cell proliferation and apoptosis, and intestinal permeability. Both GLP-1 and GLP-2 are rapidly inactivated in the circulation as a consequence of amino-terminal cleavage by the enzyme dipeptidyl peptidase IV (DP IV). The actions of these peptides on nutrient absorption and energy homeostasis and the efficacy of GLP-1 and GLP-2 in animal models of diabetes and intestinal diseases, respectively, suggest that analogs of these peptides may be clinically useful for the treatment of human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“GLP-1 increases levels of b cell cAMP and insulin gene transcription and stimulates glucose-dependent insulin release (45); however, unlike other depolarizing agents such as the sulfonylureas, b cell GLP-1R signaling is glucose dependent (46).”
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 2×
“several months of high fat feeding (30, 31).”
Self-citationDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618
Cited by
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome
Perry, R. J., Peng, L., Barry, N. A., Cline, G. W., Zhang, D., Cardone, R. L., Petersen, K. F., Kibbey, R. G., Goodman, A. L., & Shulman, G. I. (2016) · Nature · doi:10.1038/nature18309 · Cited by 1,299
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationRubino, F., Gagner, M., Gentileschi, P., Kini, S., Fukuyama, S., Feng, J., & Diamond, E. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133117.12646.48 · Cited by 639
The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Glucose Metabolism and Regulation: Beyond Insulin and Glucagon
Aronoff, S. L., Berkowitz, K., Shreiner, B., & Want, L. (2004) · Diabetes Spectrum · doi:10.2337/diaspect.17.3.183 · Cited by 569
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Browning, K. N., & Travagli, R. A. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130055 · Cited by 541
“In addition to its prominent actions to induce insulin release from pancreatic β -cells (143, 144, 478), GLP-1 also has major effects at the level of the CNS, penetrating the blood brain barrier via simple diffusion (261).”
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
Self-citationGlucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
Self-citationBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Self-citationAmino acid transporters: roles in amino acid sensing and signalling in animal cells
HYDE, R., TAYLOR, P. M., & HUNDAL, H. S. (2003) · Biochemical Journal · doi:10.1042/bj20030405 · Cited by 370
Korner, J., Bessler, M., Inabnet, W., Taveras, C., & Holst, J. J. (2007) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2007.08.004 · Cited by 344
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Chemistry and Biochemistry of Type 2 Diabetes
Ross, S. A., Gulve, E. A., & Wang, M. (2004) · Chemical Reviews · doi:10.1021/cr0204653 · Cited by 323
The prolyl oligopeptidase family
Polgár, L. (2002) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-002-8427-5 · Cited by 311
Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells
Reimann, F., & Gribble, F. M. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2757 · Cited by 292
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 273
A glucagon-like endocrine pathway in Drosophila modulates both lipid and carbohydrate homeostasis
Bharucha, K. N., Tarr, P., & Zipursky, S. L. (2008) · Journal of Experimental Biology · doi:10.1242/jeb.016451 · Cited by 239
“For example, specific genetic manipulation of the mammalian glucagon pathway is rendered difficult by the complex structure of the preproglucagon gene (Drucker, 2001).”
BackgroundConarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Szarka, L. A., Camilleri, M., Vella, A., Burton, D., Baxter, K., Simonson, J., & Zinsmeister, A. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.01.009 · Cited by 209
Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178
Ceriello, A., Esposito, K., Testa, R., Bonfigli, A. R., Marra, M., & Giugliano, D. (2011) · Diabetes Care · doi:10.2337/dc10-1949 · Cited by 134
Growth factors and beta cell replication
Vasavada, R. C., Gonzalez-Pertusa, J. A., Fujinaka, Y., Fiaschi-Taesch, N., Cozar-Castellano, I., & Garcia-Ocaña, A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.003 · Cited by 133
Peptide Receptor Radionuclide Therapy: An Overview
Dash, A., Chakraborty, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1741 · Cited by 128
“148,149 GLP-1R is mainly expressed in the b cells of the islets of the pancreas, intestine, lung, kidney, breast, and brainstem.”
Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125
MacDonald, P. E., Salapatek, A. M. F., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s443 · Cited by 103
Elkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96
Ullmer, C., Alvarez Sanchez, R., Sprecher, U., Raab, S., Mattei, P., Dehmlow, H., Sewing, S., Iglesias, A., Beauchamp, J., & Conde‐Knape, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12158 · Cited by 92
Myint, K. S., Greenfield, J. R., Farooqi, I. S., Henning, E., Holst, J. J., & Finer, N. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1065 · Cited by 77
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
“When GLP-1 is infused in Type 2 diabetics, the insulinotropic effect of GLP-1 is well preserved [15] and GLP-1 has been shown to decrease glucose levels [16,17], stimulate insulin secretion [18,19] and decrease circulating plasma glucagon levels [18,20,21].”
BackgroundC/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
Rahman, K., Liu, Y., Kumar, P., Smith, T., Thorn, N. E., Farris, A. B., & Anania, F. A. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.61 · Cited by 39
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31
“It has been proposed that GLP-1 enhances glucose disposal in an insulin-independent mechanism [46].”
BackgroundManagement of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
Dietary lipids and sweeteners regulate glucagon-like peptide-2 secretion
Sato, S., Hokari, R., Kurihara, C., Sato, H., Narimatsu, K., Hozumi, H., Ueda, T., Higashiyama, M., Okada, Y., Watanabe, C., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2012 · Cited by 27
Perspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25
Metadata
- Authors
- Drucker, D. J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2001-02-01
- Volume
- 142
- Issue
- 2
- Pages
- 521-527
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W2140137473
- Cited by
- 421
- References
- 96
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.